Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma

Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma

Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year survival rate of 18%. Although platinum-based chemotherapy remains the mainstay...

Full description

Bibliographic Details
Main Authors: Veronica Mollica, Alessandro Rizzo, Rodolfo Montironi, Liang Cheng, Francesca Giunchi, Riccardo Schiavina, Matteo Santoni, Michelangelo Fiorentino, Antonio Lopez-Beltran, Eugenio Brunocilla, Giovanni Brandi, Francesco Massari
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cancers
Subjects:
urothelial carcinoma
immunotherapy
immune checkpoint inhibitors
FGFR
antibody drug conjugates
clinical trials
Online Access:https://www.mdpi.com/2072-6694/12/6/1449

Internet

https://www.mdpi.com/2072-6694/12/6/1449

Similar Items